FERMT2 Antibody

What is FERMT2 and why are antibodies against it important for research?

FERMT2 (Fermitin Family Homolog 2), also known as Kindlin-2, KIND2, or MIG2, is a scaffolding protein critical for integrin activation. The canonical human protein consists of 680 amino acid residues with a molecular mass of 77.9 kDa and is primarily localized in the cytoplasm . FERMT2 enhances integrin activation mediated by TLN1 and/or TLN2, though it only weakly activates integrins by itself .

FERMT2 antibodies are valuable research tools because:

• FERMT2 is ubiquitously expressed across many tissue types

• It plays crucial roles in cell adhesion, migration, and signaling

• It has been implicated in multiple disease processes, including cancer progression and Alzheimer's disease

• Up to three different isoforms have been reported, requiring specific detection methods

Given FERMT2's involvement in diverse cellular processes, high-quality antibodies are essential for studying its expression patterns, protein interactions, and functional roles in normal and pathological conditions.

What experimental applications are FERMT2 antibodies commonly validated for?

FERMT2 antibodies have been validated for multiple research applications, with varying optimization requirements:

When selecting an application, consider the specific biological question and cellular context, as FERMT2 detection efficiency may vary across tissue and cell types .

How should I validate a newly acquired FERMT2 antibody?

Comprehensive validation of FERMT2 antibodies should include:

• Positive and negative controls:

  • Positive: A549 cells have been validated for Western blot and IP applications

  • Negative: CRISPR/Cas9 FERMT2 knockout cells or siRNA-treated cells

• Cross-reactivity assessment:

  • Test across relevant species if working with non-human models

  • Common validated reactivities include human, mouse, and rat samples

• Application-specific validation:

  • Western blot: Confirm 78 kDa band with appropriate reducing conditions

  • Immunostaining: Compare against published subcellular localization patterns

  • IP: Verify pull-down efficiency with known FERMT2 interacting partners

• Epitope consideration:

  • Different antibodies target different regions (e.g., C-terminal, N-terminal)

  • For example, ab194967 recognizes an epitope within amino acids 150-250

The most rigorous validation includes demonstration of signal loss in genetic knockout models or after siRNA-mediated knockdown of FERMT2 .

What tissue-specific considerations should I account for when using FERMT2 antibodies?

FERMT2 expression varies significantly across tissues, requiring tailored experimental approaches:

• Brain tissue:

  • FERMT2 is expressed in neurons and linked to Alzheimer's disease risk

  • When studying neuronal samples, co-staining with neuronal markers helps distinguish signal in mixed cell populations

  • For Alzheimer's studies, consider dual labeling with APP antibodies

• Tumor samples:

  • FERMT2 is expressed in both malignant cells and stromal components, particularly cancer-associated fibroblasts (CAFs)

  • Multiplex immunofluorescence staining with α-SMA helps identify FERMT2-positive CAFs

  • Expression correlates with immune checkpoint molecules and tumor microenvironment features

• Cardiovascular tissue:

  • Present in both heart muscle and vascular components

  • Important for detecting FERMT2's role in integrin-mediated adhesion

Tissue-specific fixation and antigen retrieval protocols may improve detection quality, with paraffin-embedded sections often requiring TE buffer (pH 9.0) or citrate buffer (pH 6.0) for optimal results .

How can I use FERMT2 antibodies to study its role in Alzheimer's disease pathology?

FERMT2 has been identified as a genetic risk factor for Alzheimer's disease (AD) and modulates APP metabolism and neuronal function . To investigate this relationship:

• Protein-protein interaction studies:

  • Co-immunoprecipitation: Use anti-FERMT2 antibodies (e.g., RRID:AB_10727911 or RRID:AB_2278298) to pull down complexes with APP, followed by Western blot with APP antibodies (RRID:AB_258409 or RRID:AB_94882)

  • Proximity ligation assay (PLA): Combine FERMT2 antibodies (RRID:AB_2278298) with APP antibodies (RRID:AB_94882) to visualize direct interactions in situ

• FERMT2 expression analysis in AD models:

  • Compare FERMT2 levels between AD and control brain tissues

  • Correlate with Aβ plaque load and tau pathology

  • The rs7143400-T allele in FERMT2's 3'UTR is associated with increased AD risk and downregulates FERMT2 expression

• Functional studies:

  • Examine how FERMT2 underexpression impacts:

    • Axonal growth

    • Synaptic connectivity (using PSD95 [RRID:AB_2619800] and Synaptophysin I [RRID:AB_887824] as markers)

    • Long-term potentiation

These approaches can help delineate how FERMT2 contributes to AD pathogenesis through its effects on APP metabolism and neuronal function.

What methods are effective for studying FERMT2's role in cancer progression and the tumor microenvironment?

FERMT2 expression correlates with unfavorable prognosis in specific cancer types and influences the tumor microenvironment (TME) . Advanced methods to investigate this include:

These methods can help elucidate FERMT2's complex roles in epithelial-mesenchymal transition, tumor progression, and modulation of the tumor immune microenvironment.

How can I optimize co-immunoprecipitation protocols for studying FERMT2 protein interactions?

Co-immunoprecipitation (Co-IP) is critical for studying FERMT2's scaffolding functions. Optimization strategies include:

• Lysis buffer selection:

  • NETN lysis buffer has been validated for FERMT2 experiments

  • For studying interactions with transmembrane proteins (like APP or integrins), consider:

    • Including 1% NP-40 or 0.5% Triton X-100

    • Adding protease and phosphatase inhibitors

    • Using gentle detergents to preserve membrane protein complexes

• IP antibody selection:

  • For FERMT2 pull-down: Use rabbit polyclonal antibodies (e.g., Proteintech 11453-1-AP)

  • Recommended amounts: 0.5-4.0 μg antibody per 1.0-3.0 mg total protein lysate

• Bead-based systems:

  • Magnetic bead approach: Pierce Protein A/G magnetic beads kit (Thermo Scientific, 88802)

  • Incubation protocol: Protein-antibody complexes with 25 μL (0.25 mg) of pre-washed A/G magnetic beads for 1 hour at 4°C

  • Washing: Three washes with co-immunoprecipitation buffer

  • Elution: Resuspend beads in loading buffer (LDS with reducing agent) for 10 minutes at room temperature

• Controls and validation:

  • Negative control: IgG from same species as primary antibody

  • Input control: 5-10% of lysate used for IP

  • Reciprocal IP: Confirm interaction by pulling down with antibodies against the interaction partner

This optimized approach facilitates reliable detection of FERMT2 interactions with partners like APP, integrins, and signaling molecules.

How can I design experiments to investigate FERMT2 isoforms and genetic variants?

FERMT2 exists in multiple isoforms and contains genetic variants with functional significance. To study these:

• Isoform-specific detection:

  • Up to three different isoforms have been reported

  • Select antibodies recognizing different epitopes to distinguish isoforms:

    • C-terminal antibodies (e.g., ARP68349_P050)

    • Antibodies targeting specific domains

  • Verify isoform size by Western blot (expected canonical size: 78 kDa)

• Genetic variant analysis (e.g., rs7143400-T in AD risk):

  • CRISPR/Cas9 genome editing:

    • Design gRNAs using tools like Benchling

    • Clone into appropriate vectors (e.g., GeneArt CRISPR OFP Nuclease Vector)

    • Use homology-directed repair with oligonucleotide templates containing the variant

    • Validate editing by Sanger sequencing

• Expression modulation by miRNAs:

  • For the rs7143400-T variant, investigate miR-4504 binding:

    • This miRNA is overexpressed in AD brains and targets FERMT2's 3'UTR

    • Measure FERMT2 levels in cells transfected with miR-4504 mimics or inhibitors

    • Validate using luciferase reporter assays with wild-type or variant 3'UTR sequences

These approaches enable mechanistic understanding of how FERMT2 genetic variants contribute to disease processes, particularly in the context of Alzheimer's disease.

What are the most effective protocols for using FERMT2 antibodies in high-content screening applications?

High-content screening with FERMT2 antibodies enables systematic analysis of its function across large datasets:

• Cell-based screening platforms:

  • For APP metabolism studies: Use HEK293 cells stably expressing APP fusion proteins (e.g., mCherry-APP695WT-YFP)

  • Transfect with siRNA libraries targeting potential FERMT2 modulators

  • Immunostain for FERMT2 and related proteins

• Quantitative image analysis parameters:

  • FERMT2 subcellular localization (cytoplasmic vs. membrane-associated)

  • Co-localization with binding partners (Pearson's correlation coefficient)

  • Cell morphological changes (spreading, adhesion, migration)

  • For neuronal studies: axonal length and branching complexity

• Multi-parameter phenotypic analysis:

  • Combine FERMT2 staining with markers for:

    • Integrins (activation status)

    • Cytoskeletal elements (α-Tubulin [RRID:AB_2210391])

    • For tumor studies: CAF markers like α-SMA

    • For neuronal studies: synaptic markers (PSD95, Homer [RRID:AB_2631222])

This high-content approach allows simultaneous assessment of multiple FERMT2-dependent cellular processes and identification of novel functional interactions.